Artelo Biosciences grants options to director

Artelo Biosciences director Robert Martin received a grant of 136 stock options to purchase common stock at an exercise price of $1.15 per share.

Rhea-AI Filing Summary

Artelo Biosciences director Robert Martin received a grant of 136 stock options to purchase common stock at an exercise price of $1.15 per share. These options expire on July 17, 2036 and will vest 100% on the earlier of the one-year anniversary of the July 17, 2026 Vesting Commencement Date or the day prior to the next annual stockholders’ meeting after that date, subject to his continued service as a Service Provider under the issuer’s plan. Following this award, he holds 136 options from this grant, and the transaction is flagged as made pursuant to a Rule 10b5-1 trading arrangement.

Insider Trade Summary 10b5-1

Grant/Award: 136 shares

Grant/Award 1 txn

Insider EMANUELE ROBERT MARTIN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	136	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 136 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.

Key Figures

Options Granted: 136 shares Exercise Price: $1.15 per share Options After Transaction: 136 shares +3 more

6 metrics

Options Granted 136 shares Stock Option (right to buy) granted to director Robert Martin

Exercise Price $1.15 per share Conversion or exercise price of the stock option grant

Options After Transaction 136 shares Total options held following this reported grant

Option Expiration Date July 17, 2036 Expiration date of the stock option award

Vesting Commencement Date July 17, 2026 Date from which the one-year vesting period is measured

Vesting Percentage 100% All shares vest on the earlier of two specified dates

Key Terms

Stock Option (right to buy), Vesting Commencement Date, Service Provider, Rule 10b5-1 trading arrangement

4 terms

Stock Option (right to buy) financial

"Security title is listed as Stock Option (right to buy) with underlying common stock"

Vesting Commencement Date financial

"Vesting Commencement Date shall mean July 17, 2026"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider through each such vesting date"

Rule 10b5-1 trading arrangement regulatory

"The transaction is flagged as made pursuant to a Rule 10b5-1 trading arrangement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARTL report for Robert Martin?

Artelo Biosciences (ARTL) reported that director Robert Martin received a grant of 136 stock options to buy common stock at $1.15 per share, expiring on July 17, 2036, subject to a specified vesting schedule and continued service.

What is the exercise price of the new ARTL stock options granted to Robert Martin?

The new options granted to director Robert Martin have an exercise price of $1.15 per share. They cover 136 shares of Artelo Biosciences common stock and represent a compensation award rather than an open-market purchase or sale.

How many ARTL shares underlie Robert Martin’s newly granted options?

Robert Martin’s award covers 136 underlying shares of Artelo Biosciences (ARTL) common stock. The Form 4 shows 136 options granted and 136 options held following the transaction, all tied to this specific stock option grant.

When do Robert Martin’s newly granted ARTL options vest and expire?

The options vest 100% on the earlier of one year after the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholders’ meeting after that date, and they expire on July 17, 2036, assuming continued service.

Are Robert Martin’s ARTL option grants tied to continued service?

Yes. The filing states vesting is conditioned on Martin continuing to be a Service Provider (as defined in the issuer’s plan) through the applicable vesting date, meaning his options vest only if he remains in qualifying service until then.

Was the ARTL insider option grant reported under a Rule 10b5-1 plan?

The Form 4 check box indicates the transaction was made under a Rule 10b5-1 trading arrangement. This designation reflects that the grant is associated with a pre-established plan framework, as recognized in the filing’s metadata.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/21/2026 - 06:27 PM Accepted by SEC EDGAR 07/21/2026 - 06:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EMANUELE ROBERT MARTIN

(Last) (First) (Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.15	07/17/2026		A		136		(1)	07/17/2036	Common Stock	136	$0.00	136	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.

	/s/ Gregory D. Gorgas, as Attorney-in-Fact	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)